Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol (PEG) electrolyte solution is a widely used osmotic laxative primarily indicated for bowel cleansing prior to colonoscopy, surgery, or radiologic examinations. The formulation consists of a high-molecular-weight, non-absorbable polymer (PEG 3350) combined with a balanced mixture of electrolytes, including sodium chloride, sodium bicarbonate, potassium chloride, and often sodium sulfate. PEG works by exerting an osmotic pressure that retains water within the intestinal lumen, thereby increasing stool volume and softening consistency to trigger peristalsis. The electrolyte component is specifically designed to be iso-osmotic with plasma, minimizing the risk of clinically significant fluid or electrolyte shifts, which is a critical safety advantage for elderly patients or those with renal or cardiac comorbidities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + electrolytes.